Acute asthma exacerbation (peds)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

For adult patients see Asthma

Background

  • An estimated 6 million children in the US have asthma
  • In 2007, asthma lead to >700,000 ED visits
  • Asthma is part of the atopy triad (asthma, allergies, eczema)
  • A history of eczema or allergies maybe helpful in making a new diagnosis of asthma
  • Wheezing in an infant is more often bronchiolitis than asthma
  • Viral URI associated with copious rhinorrea, allergen exposure, and respiratory irritants (i.e. smoke) are common precipitants for pediatric asthma exacerbations

Clinical Features

  • Wheezing
  • Cough
  • Accessory muscle use
  • Dyspnea
  • Prolonged expiration
  • Severity of retractions occurs in caudal to cephalad direction
    • Scalene muscle contractions more severe than subcostal and intercostal retractions
  • Sign of impending ventilatory failure
    • Paradoxical respiration
      • Chest deflation and abdominal protrusion during inspiration
    • Altered mental status
    • "Silent chest"

Differential Diagnosis

Pediatric Wheezing

Evaluation

  • Clinical diagnosis
  • Can consider a blood gas if there are fears that the patient is getting tired (sleepy baby vs elevated CO2?)
    • A CO2 >45 is abnormal in a patient hyperventilating and warrants close monitoring

Consider CXR

  • 1st wheezing episode
  • Asymmetric lung auscultation findings, after treatment with albuterol
  • Poor response to medications/treatment, if history and exam are not consistent with bronchiolitis
  • Worsening symptoms
  • Fever not explained by apparent viral illness

Clinical Scores

  • Diagnosis and treatment can be guided by clinical scores
    • Modified Pulmonary Index Score (MPIS - Utilized at CCMC)
    • Pediatric Asthma Score (PAS)
    • Pulmonary Score (PS)
    • Pediatric Respiratory Assessment Measure (PRAM)

Modified Pulmonary Index Score (MPIS)

Age <3 Years
Points SpO2 Acces Musc Use I:E Wheeze HR RR
0 >95% None 2:1 None; Good Aeration ≤120 ≤30
1 93-95% Mild 1:1 End Exp 121-140 31-45
2 90-92% Moderate 1:2 Insp/Exp; Good Aeration 141-160 46-60
3 <90% Severe 1:3 Insp/Exp; Poor Aeration >160 >60
Age 3-6 Years
Points SpO2 Acces Musc Use I:E Wheeze HR RR
0 >95% None 2:1 None; Good Aeration ≤100 ≤30
1 93-95% Mild 1:1 End Exp 101-120 31-45
2 90-92% Moderate 1:2 Insp/Exp; Good Aeration 121-140 46-60
3 <90% Severe 1:3 Insp/Exp; Poor Aeration >140 >60
Age ≥6 Years
Points SpO2 Acces Musc Use I:E Wheeze HR RR
0 >95% None 2:1 None; Good Aeration ≤100 ≤20
1 93-95% Mild 1:1 End Exp 101-120 21-35
2 90-92% Moderate 1:2 Insp/Exp; Good Aeration 121-140 36-50
3 <90% Severe 1:3 Insp/Exp; Poor Aeration >140 >50
  • MPIS <7 - Mild exacerbation
  • MPIS 7-10 - Moderate exacerbation
  • MPIS ≥10 - Severe exacerbation

Management

Albuterol

Favor continuous nebulization to decrease the chance of admission when compared to intermittent dosing[1]

  • Nebulizer
    • Intermitent: 2.5-5mg q20min, three doses are tradionally given back to back, then repeat as needed.
    • Continuous: 0.5mg/kg/hr (max 15mg/hr)[2]
  • MDI
    • 4-8 puffs q20min given in first hour, then q1-4hr as needed

Ipratropium

  • 0.25-0.5mg q20min, given with the first three doses of albuterol, it is shown to reduce admission.

Steroids

Should be given in the first hour with effects to reduce admission[3]

  • Dexamethasone
    • 0.6mg/kg PO or IV (max 16mg); consider 2nd dose 24-36hrs later.
      • PO and IV have equal efficacy. Giving the IV form by mouth is typically better tolerated by young children (same dosing)
    • Both 1 and 2 dose regimens as effective as prednisone or prednisolone in children [4][5]
  • Prednisone
    • 1-2mg/kg/day (60mg max) in one or two divided doses for 3-5 days
  • Methylprednisolone
    • 1mg/kg IV q 4–6hr
    • Only use IV if cannot tolerate PO since equal effectiveness between dosing routes[6]

Magnesium

  • Dose: 50mg/kg IV, max 2-4 g over 20 mins with close blood pressure monitoring
  • Smooth muscle relaxant
  • Duration of action approximately 20 min
  • In patients with moderate to severe asthma there is a decreased rate of admission with an NNT of 2[3]

Beta-agonist

  • Epinephrine
    • 1:1000 0.01mg/kg (max 0.3mg) IM, repeat as needed
  • Terbutaline
    • Given SQ, usual dose 0.01mg/kg up to 0.3mg.
    • Longer-acting beta2-agonist promoting bronchodilation

Assisted Ventilation

  • Non-invasive ventilation
    • Consider as alternative to intubation
    • Alleviates muscle fatigue which leads to larger tidal volumes
    • Maximize inspiratory support
      • Delta pressure 10
      • PEEP >4
    • May benefit from ketamine or dexmedetomidine to mildly sedate and allow the interface

Intubation

  • Push pull fluids prior to intubation to maximize the patient's preload and ideally decrease the chance of the patient arresting
  • Consider induction with Ketamine
    • Provides bronchodilation and sedation however it does promote secretions
    • Ketamine is the preferred induction agent for intubation in an asthmatic.
    • Dosing 1-2 mg/kg
  • Ventilation of asthmatic patients requires deep sedation
  • Ventilation settings
    • Assist-control ventilation
    • Resp rate
      • Start slow to avoid air-trapping and allow for longer expiration time
      • Consider I:E ratio of 1:2 or 1:3
    • Plateau pressure ideally <30
    • May require "permissive hypoventilation" and permissive hypercarbia and acidosis
      • Low peak pressure/avoidance of breath stacking more important than correcting CO2 [7]
    • Tidal volume 6-8cc/kg ideal wt
    • PEEP >4
    • Flow rate 80-100L/min
    • Keep FiO2 minimum to achieve SpO2 > 90%
  • Use bronchodilators even when intubated
  • Many patients require a continuous paralytic infusion for the first 24+ hrs of intubation

Outpatient Treatment

Severity Day Sx Night Sx Treatment (WHO 2008 Formulary)[8]
Mild intermittent, > 80% peak flow < 2/wk < 2/mo Albuterol MDI 100-200 mcg PRN QID
Mild persistent, > 80% peak flow >2/wk >2/mo Albuterol MDI 100-200 mcg PRN QID AND

Beclometasone 100-250 mcg BID

Moderate persistent, 60-80% peak flow Daily with exacerbations weekly > 1/wk Albuterol MDI 100-200 mcg PRN QID AND

Beclometasone 100-500 mcg BID AND

Salmeterol inhaled 50 mcg BID

Severe persistent, < 60% peak flow Continuous daily Frequent Albuterol MDI 100-200 mcg PRN QID AND

Beclometasone 1mg BID (high dose) AND

Salmeterol inhaled 50 mcg BID AND

theophylline, leukotriene antagonist, or PO prednisolone with taper

Disposition

  • Discharge
    • Often, patients will still have mild wheezing, but should have complete resolution of tachypnea, hypoxia, and improved work of breathing
    • A short course of glucocorticoids decreases chance of relapse [9])
    • Patient should generally continue albuterol at home q6hrs for at least the first 24hrs after discharge
    • A spacer should be prescribed to be used with the MDI to improve medication delivery to the lungs
  • Admit
    • If symptoms do not significantly improve or for severe exacerbations
  • Peak flow measurements maybe helpful when deciding disposition
    • Predicted = (30 x age (yrs)) + 30
    • PEF >70% predicted → high likelihood of successful discharge
    • PEF <40% predicted → should be admitted

See Also

External Links

References

  1. Camargo CA et al. Continuous versus intermittent beta- agonists for acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115. PMID: 14583926.
  2. National Asthma Education and Prevention Program (NAEPP), “Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,” Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
  3. 3.0 3.1 Rowe BH et al. Magnesium sulfate for treating exac- erbations of acute asthma in the emergency depart- ment. Cochrane Database Syst Rev. 2000;(2):CD001490. PMID: 10796650.
  4. Keeney, et al. Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. Pediatrics. 2013-2273
  5. Cronin et al. "A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department." Annals of EM. May 2016. 67(5):593-601
  6. Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med. Jul 1992;10(4):301-10
  7. Darioli, et al. Mechanical Controlled hypoventilation in status asthmaticus. Am Rev Respir Dis. 1984; 129 (3) 385-7
  8. Stuart MC et al. WHO Model Formulary 2008. http://www.who.int/selection_medicines/list/WMF2008.pdf.
  9. Chapman K. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. NEJM. 1991;324(12):788